Abstract Library

#4078 Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

Introduction: A single-center Phase II trial (“GI-PSMA”, NCT05547919) was conducted to evaluate prostate-specific membrane antigen (PSMA)-targeted theranostics in gastroenteropancreatic tumors.

Conference:

Presenting Author: Weich A

Authors: Weich A, Serfling S, Bayer J, Buck A, Bley T,

Keywords: neuroendocrine, PSMA-PET/CT, dosimetry, high-grade NEN, PSMA,

#3203 The efficacy of above-label doses of long-acting somatostatin analogues for the management of patients with gastroenteropancreatic tumors

Introduction: Above-label doses of long-acting somatostatin analogues (SSAs) are increasingly used for the control of secretory syndrome or as anti-proliferative treatment in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Tsoli M, Daskalakis K, Koumarianou A, Kolomodi D, Anagnostou E,

Keywords: neuroendocrine tumor, somatostatin analogues, medical treatment,

#3130 Metastatic grade 3 gastric neuroendocrine tumor expressing somatostatin receptor in Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) can occur in 30-70% of patients with MEN1. However, only 1% of GEP-NENs are Grade 3 (G3). Treatment for advanced GEP-NENs in MEN1 is based on the treatment guidelines for sporadic GEP-NENs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Graf A, Welch J, Mandl A, Parekh V, Cochran C,

Keywords: case report, multiple endocrine neoplasia type 1, gastroenteropancreatic tumor grade 3,

#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: González Devia D

Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,

Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,

#983 Vipomas: Report of Three Cases in Ten Years

Introduction: VIPoma is a rare neuroendocrine tumor (NET) with an incidence of one in 10 million per year. Most cases arise within the pancreas, with others reported in the lungs, colon, liver, adrenals, and neuroganglia.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Moletta L, Milanetto A, Liço V, De Carlo E, Alaggio R,

Keywords: vipoma, neuroendocrine tumors, pancreatic resections,